Company Description

Leveraging world-leading expertise from the fields of immunology, beta cell biology, materials science and immuno-oncology to transform the treatment of Type 1 Diabetes, EMC2 Bio is developing an antibody-nanoparticle conjugate (ANC) designed to target genetic cargo specifically to pancreatic β cells.